Get the Stockscreener App
15.42
5.79%
0.83
Eton Pharmaceuticals Inc stock is traded at $15.42, with a volume of 76,694.
It is up +5.79% in the last 24 hours and up +14.25% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$14.59
Open:
$14.67
24h Volume:
76,694
Relative Volume:
0.17
Market Cap:
$413.79M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-59.31
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
+11.12%
1M Performance:
+14.25%
6M Performance:
-4.96%
1Y Performance:
+334.79%
1-Day Range:
$14.52
$15.47
1-Week Range:
$13.85
$15.47
52-Week Range:
$3.2519
$21.48
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
15.43 | 386.98M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
152.63 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.25 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
What analysts say about Eton Pharmaceuticals Inc. stockLightning-fast capital gains - jammulinksnews.com
Eton Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
Is Eton Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
What drives Eton Pharmaceuticals Inc. stock priceExtraordinary profit generation - jammulinksnews.com
What makes Eton Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
Top Growth Companies With Insider Stakes July 2025 - simplywall.st
B. Riley Analysts Lift Earnings Estimates for ETON - Defense World
B. Riley Boosts Earnings Estimates for Eton Pharmaceuticals - Defense World
ETON’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
How Eton Pharmaceuticals Inc. stock performs during market volatilityLow Risk Profit Ideas - Newser
Why Eton Pharmaceuticals Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - Newser
Eton Pharmaceuticals: A Contrarian Play on Delayed Catalysts and Long-Term Value - AInvest
Eton Pharma Near Term Catalysts Vanish (NASDAQ:ETON) - Seeking Alpha
(ETON) Trading Report - news.stocktradersdaily.com
Institutional investors are Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) biggest bettors and were rewarded after last week's US$48m market cap gain - simplywall.st
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution By Investing.com - Investing.com South Africa
Eton Pharmaceuticals Announces Fda Acceptance of New Drug Application for Et-600 (Desmopressin Oral Solution) - MarketScreener
Eton stock gains as new therapy gets FDA review (ETON) - Seeking Alpha
Eton Pharmaceuticals announces FDA acceptance of new drug application for ET-600 - MarketScreener
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution - Investing.com
Eton Pharmaceuticals Announces FDA Acceptance of NDA for ET-600 with Target Action Date of February 25, 2026 - Quiver Quantitative
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - The Manila Times
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
Eton Pharmaceuticals to join Russell indexes - MSN
Eton Pharmaceuticals (ETON) to Join Russell 3000 and 2000 Indexes | ETON Stock News - GuruFocus
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes - The Manila Times
ETON switches auditor: Crowe LLP out, Grant Thornton in – no disputes | ETON SEC FilingForm 8-K - Stock Titan
Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc. - GuruFocus
Insiders Back These 3 High Growth Companies - Yahoo Finance
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
Bank of America Corp DE Boosts Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceu - GuruFocus
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceuticals Inc (ETON) - GuruFocus
Eton Pharma wins FDA nod for oral hydrocortisone solution - MSN
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency - MSN
Major Shareholder Increases Stake in Eton Pharmaceuticals! - TipRanks
Eton Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Trend Tracker for (ETON) - news.stocktradersdaily.com
B. Riley Forecasts Higher Earnings for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside - Seeking Alpha
Insider Sell: Sean Brynjelsen Sells 210,000 Shares of Eton Pharm - GuruFocus
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eton Pharmaceuticals Inc Stock (ETON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krempa David | Chief Business Officer |
Jun 16 '25 |
Sale |
14.73 |
10,223 |
150,585 |
612,646 |
| Krempa David | Chief Business Officer |
Jun 13 '25 |
Sale |
14.77 |
6,800 |
100,436 |
622,869 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Buy |
15.82 |
7,930 |
125,484 |
2,770,000 |
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):